SEC Launches Cohort V of the Innovators Club Welcoming Eight Life Science Start-ups
London, September 2024 - The Innovators Club, a network accelerator programme run by the Science Entrepreneur Club (SEC), has today announced its fifth cohort welcoming eight life science start-ups.
Matthew McCann
September 19, 2024
SEC and SPARK Partner to Launch BioEntrepreneur Club Midlands Chapter
The SEC and SPARK have joined forces to launch a Midlands chapter of the SEC’s BioEntrepreneur Club, a collaborative and supportive peer-to-peer community exclusively for founders and C-suite in the life sciences.
Matthew McCann
September 10, 2024
Punto Health: The Dementia Care Revolution
A dementia diagnosis can leave people feeling adrift and alone. They’re often left with mounds of questions but very limited access to personalised information or specialists. We had the opportunity to speak to Anna Muñoz Farré, founder and CEO of Punto Health, about how they are starting a dementia care revolution.
Megan Thomas
August 7, 2024
From Sugar to Surgery: The Evolution of Obesity in Plain Sight
Over two decades ago, the World Health Organization (WHO) sounded the alarm on obesity, declaring it a global epidemic. Fast forward to 2013, and the WHO set an ambitious goal: halt the rise in obesity by 2030. But with just six years left, the numbers tell a different story...
George William Ssendagala
July 11, 2024
What’s hot in biomaterials, according to investors
To find out investor’s thoughts on the biomaterials sector, we spoke to three members of our BioCapital Network; Sarah Jones - Principal at Zero Carbon Capital, Elisabetta Sakiotis - Analyst at Rockstart, and Josh Armistead-Wood - Senior Associate at Sustainable Ventures.
June 27, 2024
BoobyBiome: Pioneering Infant Health Innovation.
BoobyBiome, a start-up innovating the realm of infant health, is spearheading efforts to redefine neonatal care through a deep understanding of the gut microbiome. Founded by Lydia, Sioned, and Tara, they are dedicated to leveraging cutting-edge science to optimise infant health outcomes, particularly focusing on premature infants.
Joanna Myślińska
June 19, 2024
Biomaterials: Are they the answer to our sustainability issues?
Whilst biomaterials are entering an exciting era within regenerative medicine, it has become clear the translation of principles across industries has opened the door for biomaterials to heal the planet. In this article we showcase creative interpretations of a biomaterial and their range of potential applications in a strive towards more sustainable products.
June 12, 2024
Forge Genetics: Cutting through the genetic engineering patent thicket.
Companies looking to get innovative biology to patients around the world need to be aware that it takes a 360-degree view of the intellectual property requirements, and in the case of CRISPR this landscape is becoming more and more convoluted, with companies scrambling to renegotiate licensing laws for GMOs to use in research and industry. Taken together, this points towards an opportunity for Forge Genetics to position themselves perfectly, to create a novel, gold-standard gene-editing technology, supporting innovation throughout the global biotechnology industry.
Aonghus Topham
May 29, 2024
Revolutionizing NMR Access: The Bruker BioSpin Connexus Platform
In the ever-evolving landscape of scientificresearch, access to cutting-edge technologies and expertise is pivotal forbreakthrough discoveries. Among the array of analytical techniques, NuclearMagnetic Resonance (NMR) stands out for its ability to provide detailedinsights into the structure, dynamics, and interactions of molecules. However,the challenge lies in accessing NMR instruments and specialized analyticalservices, particularly for researchers and institutions with limited resourcesor in-house expertise.Bruker BioSpin, a pioneering leader inanalytical magnetic resonance instrumentation, has introduced an innovativesolution: Connexus. Connexus serves as adigital bridge, connecting NMR scientists with laboratories equipped withstate-of-the-art instruments and expertise.
Tobias Wingbermühle
May 15, 2024
Pentabind: AI Enhanced Aptamers Redefining Drug Discovery
PentaBind, a biotech start-up from London, aims to drug the undruggable, targeting diseases that have long been considered beyond the reach of conventional drug discovery methods. Recognising that only 15% of the human proteome has been effectively targeted by existing drugs [2], they are pioneering a novel therapeutic approach that combines the high specificity of aptamers with the power of artificial intelligence (AI).
Giovanni Maresca di Serrapriola
March 14, 2024